Potential interactions between digoxin and direct oral anticoagulants: application of cohort & novel case-crossover designs
This study aimed to examine potential drug interactions between direct oral anticoagulants (DOACs) (a drug class to prevent blood clots) and digoxin (treatment of abnormal heart rhythms). We compared a range of clinical outcomes in people prescribed DOAC and digoxin with people prescribed DOAC and beta-blockers (a treatment alternative to digoxin). We also used a new study design (case-crossover design) to compare the risk of clinical outcomes between different periods within a person as a validation. In both study designs, we found no increased risk of bleeding when DOACs are used with digoxin, suggesting combined use does not lead to drug-drug interaction. However, we found an increased risk of all-cause death associated with digoxin in DOAC users which requires further investigation.
Authors
- Charlotte Warren‐Gash (ORCID: https://orcid.org/0000-0003-4524-3180)
- Angel Y. S. Wong (ORCID: https://orcid.org/0000-0002-8618-7333)
- Liam Smeeth (ORCID: https://orcid.org/0000-0002-9168-6022)
- Krishnan Bhaskaran (ORCID: https://orcid.org/0000-0001-5364-8757)
- Ian Douglas (ORCID: https://orcid.org/0000-0002-8970-1406)
- Amitava Banerjee (ORCID: https://orcid.org/0000-0001-8741-3411)
- Clémence Leyrat (ORCID: https://orcid.org/0000-0002-4097-4577)
Institutions
- London School of Hygiene & Tropical Medicine (GB)
- Farr Institute (GB)
- University College London (GB)
Publication Details
- Journal
- Journal of Clinical Epidemiology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1016/j.jclinepi.2025.111709
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- UK Research and Innovation
- National Institute for Health and Care Research
- British Heart Foundation
- Diabetes UK
- Innovation and Technology Commission
- Medical Research Council